Respiratory pathogen detection multiplex amplification system and kit

By using multiplex fluorescent PCR amplification combined with capillary electrophoresis, a specific primer combination was designed and a human internal reference gene was added. This solved the problems of time-consuming, labor-intensive, and low-sensitivity detection of respiratory tract infection pathogens in existing technologies, and achieved high-sensitivity and specificity detection of rare pathogens in respiratory tract infections.

CN122071746APending Publication Date: 2026-05-22PEKING UNION MEDICAL COLLEGE HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610522371.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-10-14
Filing Date
2026-04-20
Publication Date
2026-05-22

AI Technical Summary

Technical Problem

Existing technologies for detecting respiratory pathogens suffer from problems such as time-consuming, labor-intensive, and low sensitivity, especially for uncommon pathogens, and cannot meet the needs for rapid and accurate diagnosis.

Method used

A detection method combining multiplex fluorescent PCR amplification and capillary electrophoresis was developed. Specific primer combinations were designed to target respiratory pathogens, including bacteria and fungi. A human internal reference gene was added, and the amplification products were detected by capillary electrophoresis, achieving rapid and accurate pathogen detection.

Benefits of technology

It achieves highly sensitive and specific detection of rare bacteria and fungi in respiratory infections, capable of detecting infections as low as 100 copies, simplifying the operation process and reducing costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122071746A_ABST
    Figure CN122071746A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of molecular detection, and particularly relates to a respiratory tract pathogen detection kit based on capillary electrophoresis and application of the respiratory tract pathogen detection kit, the kit can detect common pathogens which are possibly infected by respiratory tract patients and cannot be detected and determined through a conventional technology or a kit, and the kit at least has the technical advantages of being high in sensitivity and specificity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application belongs to the field of molecular detection technology, specifically relating to an amplification detection technology that combines multiplex fluorescence amplification with capillary electrophoresis. Background Technology

[0002] Respiratory tract infection (RTI) is one of the most common types of infectious diseases in humans, and it is also a frequent and common clinical condition, accounting for approximately 30% to 40% of infectious diseases. Respiratory tract infections are mainly caused by pathogenic microorganisms invading and multiplying in the respiratory tract. Based on the site of infection, they can be divided into upper respiratory tract infection (URI) and lower respiratory tract infection (LRI). Upper respiratory tract infections mainly include the common cold, rhinitis, pharyngitis, and laryngitis, while lower respiratory tract infections mainly include tracheitis, bronchitis, and pneumonia.

[0003] Early identification of respiratory tract infection pathogens is crucial, but due to the scarcity of specific clinical symptoms following pathogen infection, specific diagnosis still relies on laboratory testing. However, traditional pathogen detection methods often employ culture and immunoassay, which are time-consuming, cumbersome, and have low sensitivity. Furthermore, antibiotics are often administered to infected children before sampling, further reducing the positive detection rate and failing to meet the requirements for rapid diagnosis. The introduction of molecular biology methods has made early pathogen detection possible, providing accurate results without prolonged waiting times, avoiding the indiscriminate use of antibiotics and other drugs, which is of significant importance.

[0004] Furthermore, most clinically available tests currently only detect common respiratory pathogens. A significant number of patients still lack access to simple and effective testing and require more expensive, complex, and time-consuming NGS (Next-Generation Sequencing) technologies. These pathogens include bacteria, viruses, and fungi. Given the limitations of the aforementioned testing techniques, there is an urgent need for a supplementary testing method to detect these types of infections.

[0005] In view of the above, this application is hereby submitted.

[0006] Application content To address the problems in the aforementioned technologies, this application proposes an amplification system and kit for detecting uncommon respiratory pathogens, overcoming the shortcomings of existing detection products that cannot detect them and are time-consuming and labor-intensive. This system features simple operation, rapid response, high specificity, high sensitivity, high throughput, high reliability, and low cost.

[0007] Specifically, the technical solution of this application is detailed as follows: This application first proposes an amplification system or primer combination for the detection of respiratory pathogens based on capillary electrophoresis, wherein the primer composition is targeted at respiratory pathogenic bacteria and respiratory pathogenic fungi.

[0008] Furthermore, the respiratory pathogens include respiratory pathogenic bacteria (Bordetella pertussis, Citrobacter, Moraxella catarrhalis, Enterobacter cloacae, Bordetella parapertussis, Streptococcus agalactiae, Streptococcus pyogenes, Proteus vulgaris, Acinetobacter baumannii, Stenotrophomonas maltophilia, Proteus mirabilis) and respiratory pathogenic fungi (Aspergillus flavus, Aspergillus fumigatus, Pneumocystis hominis, Cryptococcus glottii, and Cryptococcus neoformans).

[0009] Furthermore, the detection system contains 11 pairs of bacteria-specific detection primers, with the following specific sequences: Furthermore, the detection system contains five pairs of fungal-specific detection primers, with the specific sequences as follows: R, S, and Y are all degenerate bases, representing G / A, C / G, and C / T, respectively.

[0010] In particular, the detection system includes not only specific detection primers for each target pathogen, but also universal detection primers for bacteria and fungi. The specific sequences of the universal detection primers are as follows: Universal upstream detection primer for bacteria: AGAGTTTGATCMTGGCTCAG (SEQ ID 33); Universal downstream detection primers for bacteria: ATGCCTCCCGTAGGAGTYTG (SEQ ID 34); Universal upstream primer for fungal detection: ACTTGGTCATTTAGAGGAAGT (SEQ ID 35); Universal downstream detection primers for fungi: GCTGCGTTCTTCATCGAYGY (SEQ ID 36); Wherein, M is a degenerate base, representing C / A.

[0011] Furthermore, in addition to bacterial and fungal specific detection primers and universal detection primers, the amplification system also contains human quality control genes. The detection primer sequences are as follows: upstream detection primer for human internal reference gene 1: ATCAGCTACTTTCCTGCAATGAGG (SEQ ID 37); Human internal reference gene 1 downstream detection primer: ATTGTACCCTTGGAGTCCAGATC (SEQ ID 38); Upstream detection primers for human internal reference gene 2: ATGGTGGGCATGGGTCAGACG (SEQ ID 39); Human internal reference gene 2 downstream detection primer: ATGTCGTCCCAGTTGGTGACG (SEQ ID 40).

[0012] In some specific configurations, the ratio of the target-specific primer to the internal reference primer to the universal primer is 2:1:1.

[0013] Furthermore, the pathogen and the quality control internal control are each labeled with two different colors of fluorescence: FAM fluorescent group labeled with FAM fluorescent pigment and HEX fluorescent group labeled with HEX fluorescent pigment.

[0014] The FAM fluorescence array includes human internal reference gene 1, 11 kinds of bacteria, and universal detection primers for bacteria. The HEX fluorescent group includes human internal reference genes 2, 5 fungi, and universal fungal detection primers; Furthermore, the detection is performed using capillary electrophoresis, and the amplification method uses multiplex fluorescent PCR (MF-PCR) amplification technology.

[0015] This application also provides a product (preferably a kit) for the detection of respiratory pathogens using multiplex amplification, which includes any of the amplification systems or primer compositions described above.

[0016] Furthermore, the kit also contains the following components: hot-start Taq DNA polymerase, UDG enzyme and 2×PCR amplification buffer, quality control, nuclease-free purified water and internal standard (QD550h), etc.

[0017] The detection kit described in this application uses multiplex fluorescent PCR (MF-PCR) to amplify the target, and then detects the amplification products by capillary electrophoresis, which is a multiplex fluorescent fragment analysis technique to complete the detection of clinical samples.

[0018] This application also provides a method for detecting respiratory pathogens, including the step of amplifying a sample using the above-described amplification system or primer combination; or the step of detecting a sample using the above-described kit.

[0019] Specifically, it includes the following steps: sample processing and extraction of genomic DNA, preparation of PCR system and PCR amplification using the aforementioned primer combination, detection of amplification products using a genetic analyzer, data analysis and interpretation of detection results.

[0020] Compared with the prior art, the advantages of this application include at least the following: This application covers rare bacteria and fungi in respiratory infections, encompassing a wide range of detection targets. It enables early detection of pathogens that cannot be detected by conventional kits, serving as a supplementary diagnostic method for cases where conventional methods / kits cannot detect the presence of uncommon pathogens in patients. The system also incorporates universal primers for pathogen detection and human internal reference gene detection, ensuring both sample collection and infection detection.

[0021] This application, through repeated optimization of the primer sequence system in the high-gravity system, finally established a primer system based on capillary electrophoresis detection. Validated by experimental and clinical samples, this invention has high detection sensitivity and strong specificity, and can detect and identify infections as low as 100 copies, demonstrating significant clinical significance. Attached Figure Description

[0022] To more clearly illustrate the technical solutions in the specific embodiments of this application or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0023] Figure 1 Results of preliminary primer mixing test for pathogens; Figure 2 Results of primer specificity test for Enterobacter cloacae; among which, Figure 2 A represents the CE test primer results; Figure 2 B represents the result of the dye method test; Figure 3 , Average peak height of each concentration gradient detection peak; Figure 4 The quality control test results are shown in the image; where A is the negative control and B is the quality control sample. Figure 5 Inconsistent CE repeated test results for samples; among which Figure 5 A is the peak diagram of the three-repeated FAM group; Figure 5 B represents the peak statistics of the three-repeated FAM group. Detailed Implementation

[0024] Those skilled in the art can refer to the content of this document to implement its application. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included within this application. The preparation methods and applications of this application have been described through preferred embodiments. Those skilled in the art can obviously modify or appropriately change and combine the preparation methods and applications described herein without departing from the content, spirit, and scope of this application to implement and apply the technology of this application. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0025] The following terms or definitions are provided merely to aid in understanding this application. These definitions should not be construed as having a scope less than that understood by those skilled in the art.

[0026] Unless otherwise defined below, all technical and scientific terms used in the specific embodiments of this application are intended to have the same meaning as commonly understood by those skilled in the art. While it is believed that the following terms will be well understood by those skilled in the art, the following definitions are set forth to better explain this application.

[0027] As used herein, the terms “comprising,” “including,” “having,” “containing,” or “involving” are inclusive or open-ended and do not exclude other unlisted elements or method steps. The term “consisting of” is considered a preferred embodiment of the term “comprising.” If a group is defined below as comprising at least a certain number of embodiments, this should also be understood to disclose a group that preferably consists only of those embodiments.

[0028] When referring to a singular noun, the indefinite or definite article used, such as "a" or "a kind of," "the," includes the plural form of the noun.

[0029] The terms "approximately" and "generally" in this application refer to an accuracy range that, as would be understood by those skilled in the art, still guarantees the technical effects of the mentioned features. This term typically indicates a deviation from the indicated value of ±10%, preferably ±5%.

[0030] Terms such as "or more," "at least," and "more than," for example, "at least one," should be understood to include, but are not limited to, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000 or more of the stated values. This also includes any larger numbers or fractions in between.

[0031] Conversely, the term "not exceeding" includes every value less than the stated value. For example, "not exceeding 100 nucleotides" includes 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 5 4, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, and 0 nucleotides. Also includes any smaller numbers or fractions in between.

[0032] The terms "multiple," "at least two," "two or more," and "at least the second" should be understood to include, but are not limited to, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, and 70. 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000 or more. Also includes any larger numbers or fractions in between.

[0033] The technical solutions of this application will now be clearly and completely described with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of this application. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.

[0034] Example 1: Design and screening of primers for combined detection of respiratory pathogens In response to the current lack of effective detection methods for uncommon respiratory pathogens in clinical practice, the applicant compiled and statistically analyzed clinical patient data from hospitals to identify the following respiratory pathogens that are clinically significant but easily missed by routine testing as detection targets: Bordetella pertussis, Citrobacter, Moraxella catarrhalis, Enterobacter cloacae, Bordetella parapertussis, Streptococcus agalactiae, Streptococcus pyogenes, Proteus vulgaris, Acinetobacter baumannii, Stenotrophomonas maltophilia, Proteus mirabilis, Aspergillus flavus, Aspergillus fumigatus, Pneumocystis hominis, Cryptococcus grease, and Cryptococcus neoformans.

[0035] To design highly species-specific primers for these pathogens, it is necessary to screen for specific target genes of each respiratory pathogen. The applicant adopted the following strategies to screen for specific target genes of each pathogen: a) Based on intraspecific comparison: Download the genomes of each bacterium / fungus through NCBI, and identify highly conserved "core genes" common to all strains within the species, and remove strains with <95% core gene homology; b) Based on interspecific comparison: Cross-search the candidate "core genes" with the GenBank bacterial / fungal database, and retain as many segments as possible with intraspecific coverage ≥98% and interspecific homology <80%. In addition, considering the relevance of target function to clinical practice, this application prioritizes genes related to virulence / resistance, cell wall synthesis, or spore surface proteins, or genes with high conservation such as Acinetobacter baumannii ompA (outer membrane protein A, highly conserved and virulence core), Cryptococcus neoformans CAP10 (capsular polysaccharide synthase), and Aspergillus flavus AflR (core transcriptional regulatory gene for aflatoxin synthesis). This allows the test results to directly or indirectly indicate key clinical concerns.

[0036] Based on the specific genes or sequences of each strain obtained through screening, primers for specific detection are designed. During primer design, the primer length should be set at 18-30 bp; the Tm value of primers at each locus should be kept as consistent as possible (around 60℃); primer dimers, hairpins, and other structures should be avoided as much as possible; there should be no more than 3 complementary bases at the 3′ end of the primer pair, and the last 5 bases at the 3′ end should preferably be mismatched with the genome of closely related species by ≥2 bases; the length of PCR amplification fragments should be limited to the range of 100-500 bp as much as possible.

[0037] Furthermore, considering the large proportion of human host samples obtained during sampling, the ease with which housekeeping genes can be amplified, and the issues of pathogen detection coverage and specificity, the primers were modified during primer design, including base mismatch, degenerate base modification, and fluorescence modification. This was done to control efficiency and specificity while ensuring sufficient primer usage and preventing primer degradation due to expiration dates or improper storage, which could lead to misinterpretations, missed detections, or abnormal results. Examples include sequences SEQ ID NO. 12, 13, 20, and 21 in this application.

[0038] This application describes high-repetition amplification in a single system, ensuring balanced amplification of each target species or gene in a multiplex system, which is crucial for accurate detection results. In the initial design of the multiplex primer system, the applicant performed mixed amplification using various bacterial-specific primers. For example, the preliminary primer sequences used are shown in the table below, and the test results are as follows. Figure 1 After preliminary mixing of several pathogen-specific primers (primer ratio 1:1:1:1:1:1:1:1:1:1:1), the test results showed that in addition to the specific peaks, there were also several non-specific peaks. Figure 1(As indicated in the box), and the ratio of the lowest peak height to the highest peak height for each detection target was 23.91%, with a CV value of 47%, indicating significant differences in the uniformity of the initial mixed test. Analysis of these test results suggests that direct mixing may lead to primer interactions, inter-species interference, or other mutual influences.

[0039] In the table, Y, W, and R are all degenerate bases, representing C / T, A / T, and A / G, respectively.

[0040] Therefore, adjustments need to be made to the primers during the screening process, followed by secondary adjustments and design. To ensure the development cycle and control costs (due to the long and costly synthesis of fluorescent primers), and to guarantee the stability of the system and the accuracy of the results, CE verification testing is conducted based on the dye method to ensure the primers' effectiveness. The two main screening evaluation aspects, exemplarily, include specificity and amplification efficiency.

[0041] Regarding specificity, the CE method was used for cross-experimentation during the screening process, and compared with the dye method (KAPA SYBR®FAST qPCR Master Mix Kit, purchased from Roche) to test and verify the effectiveness of each detection target under the CE method in detecting non-target targets. The pathogens used in the experiment included *Streptococcus pneumoniae*, *Klebsiella pneumoniae*, *Moraxella catarrhalis*, *Bordetella pertussis*, *Legionella pneumophila*, *Serratia marcescens*, *Streptococcus agalactiae*, *Enterobacter cloacae*, *Streptococcus pyogenes*, *Klebsiella pneumoniae*, *Klebsiella pneumoniae*, *Escherichia coli*, *Staphylococcus aureus*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, *Bordeauxella parapertussis*, *Haemophilus influenzae*, *Proteus vulgaris*, *Proteus mirabilis*, *Cryptococcus neoformans*, *Cryptococcus grease*, *Aspergillus flavus*, *Aspergillus fumigatus*, *Pneumocystis hominis*, *Citrobacter freundii*, *Citrobacter kurstii*, and other respiratory pathogens that may cause infection (each strain was obtained from ATCC, the Microbial Strains Center of the Institute of Microbiology, Chinese Academy of Sciences, and clinical isolates from hospitals). The following are the detection results of primers established after screening: Note: "√" indicates specificity, "-" indicates no product. The cross-test results showed that the primers for detecting each pathogen were effective in amplifying and detecting each single target, while not amplifying other pathogen targets. For example... Figure 2 Taking the partial test results of Enterobacter cloacae-specific primers as an example, it can be clearly seen that when using strains other than Enterobacter cloacae as templates (10... 4When amplified by copying, the CE test results were consistent with the dye method test results. No non-specific peaks were detected in the non-target peak detection, while different strains of Enterobacter cloacae were used as templates (10...). 3 When copying, it can specifically detect the target peak.

[0042] Regarding amplification efficiency, the main considerations were the uniformity and stability of amplification in the CE system. Therefore, the qPCR dye method (KAPA SYBR® FAST qPCR Master Mix Kit, purchased from Roche) was used to test primer amplification efficiency during screening. The test results are shown in the table below. The dye method test results show that the Ct values ​​of the target-specific primers for detecting the corresponding pathogens ranged from 14 to 19. Taking the Ct values ​​of universal primers into account, the coefficient of variation (CV) of the Ct values ​​of each primer was 6% (<10%). If universal primers were not considered, the coefficient of variation (CV) of the Ct values ​​of each target primer was 3% (<10%). Relatively speaking, the efficiency difference of the primers was small.

[0043] Considering that the detection target results of this application are affected not only by whether an infection has occurred, but also by the sampling process, a human internal reference gene was designed to determine whether a sample was obtained. Therefore, the human housekeeping gene was selected as the internal reference control for this application. The specific primers for the internal reference gene are as follows: Through a series of repeated optimizations and screenings, the primer system finally determined in this application is as follows: R, S, Y, and M are all degenerate bases, representing G / A, C / G, C / T, and C / A, respectively.

[0044] After adjusting and selecting the primers, this application also tested the concentration of each primer in the primer combination according to the efficiency test results to establish the ratio of primers at each site. Specifically, the target-specific primer: internal reference primer: universal primer ratio of 2:1:1 showed the best results.

[0045] Example 2: Evaluation of Detection Performance In addition to its excellent specificity, this application serves as a supplement to conventional methods that cannot detect certain pathogens (bacteria / fungi), and can not only determine whether an infection is caused by a pathogen, but also specifically identify the pathogen causing the infection.

[0046] In addition, compared with commercially available kits, another significant advantage of this application is that it can simultaneously detect one or more pathogens causing human respiratory tract infections in a single tube, and the detection sensitivity can reach 100 copies.

[0047] To demonstrate the aforementioned significant characteristics, the following experimental tests were conducted in this embodiment: Select DNA from 16 target-positive bacteria, and analyze them according to a 10... 1 Copy / ul, 5×10 1 Copy / ul, 7.5×10 1 Copy / ul, 10 2 Copy / ul, 2.5×10 2 Copy / ul, 5×10 2 The sample was diluted and mixed using a copy / ul concentration gradient, and 10 ng of human genomic DNA was incorporated into each gradient. Each concentration gradient was amplified and detected five times. The results of each concentration sample were statistically analyzed, and the average peak heights of the internal control peak and indicator peak are shown in the table below: As shown in the table above, the coefficients of variation of the indicator peak and the internal reference peak of this method system are both less than 10%, indicating that the peaks have good stability and will not change significantly due to differences in sample size. Therefore, they can effectively guide the interpretation of the results.

[0048] Based on the test results, statistical analysis was performed on the average peak heights of each detection peak at different concentrations. Specific test statistical results can be found in [link to data]. Figure 3 .from Figure 3 It can be seen that when the sample size is 10 2 When the sample size is 10 or higher, the average peak height of each target is above the corresponding indicator peaks IntFC2 and IntHC2, which allows for a clearer interpretation of the results. However, when the sample size is less than 10, the average peak height of each target is above the corresponding indicator peaks IntFC2 and IntHC2. 2 During copying, it is also clearly visible from the result image that 5×10 1 Copy template size and 7.5 × 10 1 When copying templates, it can also distinguish them quite well.

[0049] In summary, this method can stably detect pathogens with a template quantity of 100 copies, and can also provide indication for pathogens with a quantity as low as 75 copies, demonstrating good sensitivity.

[0050] Example 3: Preparation and application of a combined detection kit for respiratory pathogens This embodiment is equipped with a respiratory pathogen composite detection kit, which includes RSP primer mixture, PCR amplification buffer, enzyme mixture, quality control (negative and positive), molecular weight internal standard QD550h, and nuclease-free pure water.

[0051] The primer combination included in the kit is as determined in Example 1, and all primers are mixed in proportions determined by experimentation to prepare a 10× primer mix.

[0052] The kit also includes an enzyme mixture containing Taq DNA polymerase and UDG enzyme. The former is used for amplification of PCR products, and the latter is used to prevent the amplification system from being contaminated by dUTP fragments in the environment or to prevent products from escaping into the environment and causing contamination to subsequent PCR amplification.

[0053] In particular, the kit also includes a molecular weight internal standard QD550h, which, compared to conventional internal standards, incorporates an exogenous fragment to indicate the interpretation of results.

[0054] In addition, the PCR amplification buffer contained in the kit includes dATP, dTTP, dCTP, dGTP, dUTP, and Mg. 2+ wait.

[0055] The specific operating procedure for using the reagent kit is as follows: I. Sample Preparation: DNA was extracted from pretreated respiratory clinical samples (sputum, nasopharyngeal swabs, bronchoalveolar lavage fluid) using the ZYMO Quick-DNA Fungal / Bacterial Miniprep Kit. The concentration and purity of the DNA were determined using a NanoDrop2000 (Thermo). The DNA was then diluted to the appropriate concentration and stored at 4°C or -20°C for later use.

[0056] II. Testing Steps Step 1: Preparation / dispensing of PCR amplification system (completed in the reagent preparation area) Prepare the PCR amplification system according to the components in the table below. After vortexing and mixing, dispense 19 μL into each tube according to the number of samples.

[0057] Step 2: Add template (completed in the specimen preparation area) Add 1 μL of each prepared clinical DNA sample to the corresponding PCR reaction tube. At the same time, set up quality control controls (quality control: 1 μL quality control product, negative control: 1 μL nucleic acid-free pure water).

[0058] Step 3: PCR amplification (completed in the amplification region) Place each reaction tube into the reaction chamber of the PCR amplification instrument and set the reaction volume to 20µL.

[0059] Follow the reaction procedure below to set up and amplify PCR: Step 4: Detection of amplified products (completed in the product detection laboratory) Prepare the loading mixture of molecular weight internal standard and deionized formamide: (0.2 μL molecular weight internal standard + 8.8 μL formamide) × number of samples to be tested. Vortex to mix for 10-15 seconds. Use a pipette to dispense 9 μL of the deionized formamide and internal standard mixture into each test well. Add 1 μL of the amplification product (stock solution) to the deionized formamide and internal standard mixture, and cover with the sealing tape. Perform the test according to the steps in the genetic analyzer user manual.

[0060] Step 5: Data Analysis After the genetic analyzer completes the test, GeneMapper software is used to analyze the raw data (.fsa file) from the test.

[0061] Step 6: Interpretation of Results To interpret the test results, it is necessary to first interpret the results of each control sample to determine whether there is any contamination or abnormality in the quality control materials (see quality control test results). Figure 4 The negative control should only show an indicator peak, and the quality control should show the corresponding target peak within each detection panel and bin, in addition to a normal indicator peak. Then, each test result should be checked to determine whether any product peaks exceed the instrument's detection peak height threshold. If such a situation occurs, contamination investigation, reagent quality investigation, and product re-dilution and retesting should be carried out accordingly.

[0062] Once the experimental quality control checks are completed and the results meet the standards, the clinical samples can be interpreted. If no peak is observed for the human internal reference target, it indicates an abnormality in the sampling. The corresponding results should not be interpreted, and the sample should be resampled.

[0063] The presence of a peak at the human internal control target indicates successful sampling. The results of the test for this sample should first be interpreted using the universal detection panel for bacteria and fungi. If a product peak appears within the universal detection panel range and is located within the bin range, it indicates that there may be an infection by a pathogen within the detection range of this kit. Further interpretation of specific infection is then required. If the peak height of the target sample is greater than 175 rfu, and is also greater than the corresponding indicator peak (IntFC2 and / or IntHC2), it indicates the presence of a corresponding bacterial and / or fungal infection. If the peak height is greater than the corresponding indicator peak (IntFC1 and / or IntHC1) but less than the corresponding indicator peak (IntFC2 and / or IntHC2), it can only be determined that a corresponding bacterial and / or fungal infection may exist, and sample enrichment is required for further detection and determination, or the sampling time may be delayed before detection and determination. If the peak height is greater than the corresponding indicator peak (IntFC1 and / or IntHC1), it can be determined that no corresponding bacterial and / or fungal infection was found within the detection range, and further investigation is needed to check for other pathogens outside the detection range.

[0064] If a product peak appears within the panel range for general bacterial and / or fungal detection, but not within the corresponding bin range, it can be determined that there is an infection by other pathogens within the non-specific target detection range, and other methods can be used to further identify the corresponding pathogens.

[0065] If no product peak is detected within the panel range for both bacteria and / or fungi, it can be determined that the sample was not infected by any pathogens within the detection range in this test.

[0066] Example 4: Detection of Clinical Samples The hospital collects clinical samples, uses the aforementioned kit from this application for amplification and capillary electrophoresis detection, and compares the results with NGS / Sanger sequencing and clinical culture results to evaluate the effectiveness of the amplification system and kit from this application for clinical testing.

[0067] Obtain specimens with a clinical diagnosis of respiratory infection (positive hospital clinical culture) or suspected respiratory infection (negative respiratory infection test kit results and clinical culture, but with clinical symptoms of respiratory infection). Extract DNA from the processed respiratory patient clinical samples using the ZYMO Quick-DNA Fungal / Bacterial Miniprep Kit. Follow the kit instructions for specific procedures. The prepared DNA samples were then analyzed for quality and concentration using a NanoDrop2000 (Thermo) and stored at 4°C for later use.

[0068] The extracted clinical sample DNA was amplified and detected according to Example 3. The specific amplification and detection results are shown in the table below: Note that in the table, "+" indicates a peak or a positive result, and "-" indicates no peak, a negative result, or unsuccessful culture. * indicates a sample; increasing the sample volume will result in a positive result. This embodiment tested a total of 97 clinical samples. The above results show 25 positive CE results and a comparison with NGS / Sanger sequencing results. The results showed that in one sample, RSP013, only *Streptococcus pyogenes* was amplified during testing, while *Malva maltophilia* target sites showed peaks, but the peak height was between IntFC1 and IntFC2, in the gray region. The results of three repeated CE tests were consistent (for repeated tests with a 10ng loading, see [link to relevant documentation]). Figure 5 Therefore, the sample was determined to be positive for Streptococcus pyogenes. Apart from this, the CE test results for all other samples were included in the NGS / Sanger sequencing results, and the universal primer amplification results for the CE results were consistent with the NGS / Sanger sequencing results. Furthermore, the corresponding culture results were mostly negative or failed to culture, indicating that the kit in this application can not only accurately detect pathogens within the target coverage area but also indicate pathogens that may cause infection outside the target coverage area.

[0069] The reagent kit described in this application has been tested on clinical samples and compared with different methods, demonstrating that it has high sensitivity and accuracy and can objectively and accurately detect clinical samples.

[0070] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit it. Although this application has been described in detail with reference to the foregoing embodiments, it should be understood in the art that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of this application.

Claims

1. A primer composition for detecting respiratory pathogens based on capillary electrophoresis, characterized in that, The primer set targets respiratory pathogenic bacteria and respiratory pathogenic fungi.

2. The primer composition according to claim 1, characterized in that, The respiratory pathogenic bacteria include Bordetella pertussis, Citrobacter, Moraxella catarrhalis, Enterobacter cloacae, Bordetella parapertussis, Streptococcus agalactiae, Streptococcus pyogenes, Proteus vulgaris, Acinetobacter baumannii, Stenotrophomonas maltophilia, and Proteus mirabilis; the respiratory pathogenic fungi include Aspergillus flavus, Aspergillus fumigatus, Pneumocystis hominis, Cryptococcus glottii, and Cryptococcus neoformans.

3. The primer composition according to any one of claims 1-2, characterized in that, The primer sequences are shown below: R, S, and Y are all degenerate bases, representing G / A, C / G, and C / T, respectively.

4. The primer composition according to claim 3, characterized in that, The primer composition further includes universal detection primers with the following sequences: Universal upstream detection primer for bacteria: AGAGTTTGATCMTGGCTCAG (SEQ ID NO.33). Universal downstream detection primers for bacteria: ATGCCTCCCGTAGGAGTYTG (SEQ ID NO.34). Universal upstream primer for fungal detection: ACTTGGTCATTTAGAGGAAGT (SEQ ID NO.35) Universal downstream primers for fungal detection: GCTGCGTTCTTCATCGAYGY (SEQ ID NO.36). Wherein, M is a degenerate base, representing C / A.

5. The primer composition according to claim 4, characterized in that, The primers also include internal control primers with the following sequences: upstream primer for human internal reference gene 1 detection: ATCAGCTACTTTCCTGCAATGAGG (SEQ ID NO.37). Downstream detection primers for human internal reference gene 1: ATTGTACCCTTGGAGTCCAGATC (SEQ ID NO.38). Upstream detection primers for human internal reference gene 2: ATGGTGGGCATGGGTCAGACG (SEQ ID NO.39). Human internal reference gene 2 downstream detection primer: ATGTCGTCCCAGTTGGTGACG (SEQ ID NO.40).

6. The primer composition according to claim 5, characterized in that, The primers are labeled with two fluorescent markers: FAM fluorescent group labeled with FAM fluorescein and HEX fluorescent group labeled with HEX fluorescein. The FAM fluorescent group includes primers for human internal reference gene 1, bacterial primers, and universal bacterial detection primers; The HEX fluorescent group includes primers for the human internal reference gene 2, fungal primers, and universal fungal detection primers.

7. A product for the detection of respiratory pathogens using multiplex amplification assays, characterized in that, The product includes the primer composition according to any one of claims 1-6; preferably, the product is a kit.

8. The product according to claim 7, characterized in that, The product further includes: hot-start Taq DNA polymerase, UDG enzyme and 2×PCR amplification buffer, quality control, nuclease-free purified water and internal standard.

9. The use of the primer composition according to any one of claims 1-6 in the detection of respiratory pathogens, or in the preparation of a respiratory pathogen detection kit.

10. A method for detecting respiratory pathogens, characterized in that, The steps of amplifying a sample using any primer composition of claims 1-6, or detecting a sample using any kit of claims 7-8.